[Balch, C.M., Buzaid, A.C., Soong, S.J., Atkins, M.B., Cascinelli, N., Coit, D.G., Fleming, I.D., Gershenwald, J.E., Houghton, A., Jr., Kirkwood, J.M., McMasters, K.M., Mihm, M.F., Morton, D.L., Reintgen, D.S., Ross, M.I., Sober, A., Thompson, J.A., Thompson. J.F. (2001). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol., 19(16), 3635-3648.10.1200/JCO.2001.19.16.3635]Search in Google Scholar
[Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., Sondak, V. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 406(6795), 536-540.]Search in Google Scholar
[Blackwood, M. A., Holmes, R., Synnestvedt, M., Young, M., George, C., Yang, H., Elder D. E., Schuchter, L. M., Guerry, D., Ganguly, A. (2002). Multiple primary melanoma revisited. Cancer., 94(8), 2248-2255.10.1002/cncr.10454]Search in Google Scholar
[Byrd, K.M., Wilson, D.C., Hoyler, S.S., Peck, G.L. (2004). Advanced presentation of melanoma in African Americans. J. Amer. Acad. Dermatol., 50(1), 142-143.10.1016/S0190-9622(03)02091-7]Search in Google Scholar
[Clark, W.H. Jr., Elder, D.E., Guerry, D. 4th, Epstein, M.N., Greene, M.H., Van Horn, M. (1984). A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol., 15(12), 1147-1165.10.1016/S0046-8177(84)80310-X]Search in Google Scholar
[Curtin, J.A., Fridlyand, J., Kageshita, T., Patel, H.N., Busam, K.J., Kutzner, H., Cho, K.H., Aiba, S., Brocker, E.B., LeBoit, P.E., Pinkel, D., Bastian, B.C. (2005). Distinct sets of genetic alterations in melanoma. New Engl. J. Med., 353(20), 2135-2147.10.1056/NEJMoa05009216291983]Search in Google Scholar
[Danen, E.H., Ten Berge, P.J., Van Muijen, G.N., Van't Hof-Grootenboer, A.E., Brocker, E.B., Ruiter, D.J. (1994). Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology, 24(3), 249-256.10.1111/j.1365-2559.1994.tb00517.x7515372]Search in Google Scholar
[Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G.D., Perrone, F., Luoni, C., Suardi, S., Frattini, M., Pilotti, S., Anichini, A., Tragni, G., Parmiani, G., Pierotti, M.A., Rodolfo, M. (2004). BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene, 23(35), 5968-5977.10.1038/sj.onc.120778015195137]Search in Google Scholar
[Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., Futreal, P.A. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954.]Search in Google Scholar
[de Snoo, F.A., Hayward, N.K. (2005). Cutaneous melanoma susceptibility and progression genes. Cancer Lett., 230(2), 153-186.10.1016/j.canlet.2004.12.03316297704]Search in Google Scholar
[Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., van den Oord, J.J. (2001). Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol., 117(6), 1483-1489.10.1046/j.0022-202x.2001.01601.x11886512]Search in Google Scholar
[Dhawan, P., Singh, A.B., Ellis, D.L., Richmond, A. (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res., 62(24), 7335-7342.]Search in Google Scholar
[Diepgen, T.L., Mahler, V. (2002). The epidemiology of skin cancer. Brit. J. Dermatol., 146 (Suppl. 61), 1-6.10.1046/j.1365-2133.146.s61.2.x11966724]Search in Google Scholar
[Du, J., Miller, A.J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., Fisher, D.E. (2003). MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Amer. J. Pathol., 163(1), 333-343.10.1016/S0002-9440(10)63657-7]Search in Google Scholar
[Duncan, L.M., Deeds, J., Cronin, F.E., Donovan, M., Sober, A.J., Kauffman, M., McCarthy, J.J. (2001). Melastatin expression and prognosis in cutaneous malignant melanoma. J. Clin. Oncol., 19(2), 568-576.10.1200/JCO.2001.19.2.568]Search in Google Scholar
[Edwards, R.H., Ward, M.R., Wu, H., Medina, C.A., Brose, M.S., Volpe, P., Nussen-Lee, S., Haupt, H.M., Martin, A.M., Herlyn, M., Lessin, S.R., Weber, B.L. (2004). Absence of BRAF mutations in UV-protected mucosal melanomas. J. Med. Genet., 41(4), 270-272.10.1136/jmg.2003.016667]Search in Google Scholar
[Felding-Habermann, B., Fransvea, E., O'Toole, T.E., Manzuk, L., Faha, B., Hensler, M. (2002). Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis, 19(5), 427-436.10.1023/A:1016377114119]Search in Google Scholar
[Garbe, C., McLeod, G.R., Buettner, P.G. (2000). Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer, 89, 1269-1278.10.1002/1097-0142(20000915)89:6<1269::AID-CNCR11>3.0.CO;2-C]Search in Google Scholar
[Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., Beroukhim, R., Milner, D.A., Granter, S.R., Du, J., Lee, C., Wagner, S.N., Li, C., Golub, T.R., Rimm, D.L., Meyerson, M.L., Fisher, D.E., Sellers, W.R. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436(7047), 117-122.]Search in Google Scholar
[Goldstein, A.M., Chan, M., Harland, M., Hayward, N.K., Demenais, F., Timothy Bishop, D., Azizi, E., Bergman, W., Bianchi-Scarra, G., Bruno, W., Calista, D., Cannon Albright, L.A., Chaudru, V., Chompret, A., Cuellar, F., Elder, D.E., Ghiorzo, P., Gillanders, E.M., Gruis, N.A., Hansson, J., Hogg, D., Holland, E.A., Kanetsky, P.A., Kefford, R.F., Teresa Landi, M., Lang, J., Leachman, S.A., Mackie, R.M., Magnusson, V., Mann, G.J., Newton Bishop, J., Palmer, J.M., Puig, S., Puig-Butille, J.A., Stark, M., Tsao, H., Tucker, M.A., Whitaker, L., Yakobson, E. (2007). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J. Med. Genet., 44(2), 99-106.10.1136/jmg.2006.043802]Search in Google Scholar
[Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A.N., Busam, K., Polsky, D. (2003). Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res., 63(14), 3955-3957.]Search in Google Scholar
[Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: A role for p16? Br. J. Cancer, 95(4), 496-505.10.1038/sj.bjc.6603283]Search in Google Scholar
[Hammock, L., Cohen, C., Carlson, G., Murray, D., Ross, J.S., Sheehan, C., Nazir, T.M., Carlson, J.A. (2006). Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J. Cutan. Pathol., 33(9), 599-607.10.1111/j.1600-0560.2006.00501.x]Search in Google Scholar
[Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B.L., Federman, S., Miller, J.R. 3rd, Allen, R.E., Singer, M.I., Leong, S.P., Ljung, B.M., Sagebiel, R.W., Kashani-Sabet, M. (2005). The gene expression signatures of melanoma progression. Proc. Natl. Acad. Sci. USA, 102(17), 6092-6097.10.1073/pnas.0501564102]Search in Google Scholar
[Hofmann, U.B., Westphal, J.R., Waas, E.T., Becker, J.C., Ruiter, D.J., van Muijen, G.N. (2000) Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J. Invest. Dermatol., 115(4), 625-632.10.1046/j.1523-1747.2000.00114.x]Search in Google Scholar
[Hornberg, J.J., Bruggeman, F.J., Westerhoff, H.V., Lankelma, J. (2006). Cancer: A Systems Biology disease. Biosystems, 83(2-3), 81-90.10.1016/j.biosystems.2005.05.014]Search in Google Scholar
[Hsu, M.Y., Meier, F.E., Nesbit, M., Hsu, J.Y., Van Belle, P., Elder, D.E., Herlyn, M. (2000a). E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Amer. J. Pathol., 156(5), 1515-1525.10.1016/S0002-9440(10)65023-7]Search in Google Scholar
[Hsu, M., Andl, T., Li, G., Meinkoth, J.L., Herlyn, M. (2000b). Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J. Cell Sci., 113 (Pt 9), 1535-1542.10.1242/jcs.113.9.1535]Search in Google Scholar
[Jiveskog, S., Ragnarsson-Olding, B., Platz, A., Ringborg, U. (1998). N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol., 111(5), 757-761.10.1046/j.1523-1747.1998.00376.x]Search in Google Scholar
[Kumar, R., Angelini, S., Snellman, E., Hemminki, K. (2004). BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol., 122(2), 342-348.10.1046/j.0022-202X.2004.22225.x]Search in Google Scholar
[Li, X., Regezi, J., Ross, F.P., Blystone, S., Ilic, D., Leong, S.P., Ramos, D.M. (2001). Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro. J. Cell Sci., 114(Pt 14), 2665-2672.10.1242/jcs.114.14.2665]Search in Google Scholar
[Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., Eng, C., Parsons, R. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16(1), 64-67.10.1038/ng0597-64]Search in Google Scholar
[Miller, A.J., Mihm, M.C. Jr. (2006). Melanoma. New Engl. J. Med., 355(1), 51-65.10.1056/NEJMra052166]Search in Google Scholar
[Ortega, S., Malumbres, M., Barbacid, M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta, 1602(1), 73-87.10.1016/S0304-419X(02)00037-9]Search in Google Scholar
[Papp, T., Pemsel, H., Zimmermann, R., Bastrop, R., Weiss, D.G., Schiffmann, D. (1999). Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet., 36(8), 610-614.]Search in Google Scholar
[Petitelerc, E., Stromblad, S., von Schalscha, T.L., Mitjans, F., Piulats, J., Montgomery, A.M., Cheresh, D.A., Brooks, P.C. (1999). Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res., 59(11), 2724-2730.]Search in Google Scholar
[Pollock, P.M., Harper, U.L., Hansen, K.S., Yudt, L.M., Stark, M., Robbins, C.M., Moses, T.Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N.K., Trent, J.M., Meltzer, P.S. (2003). High frequency of BRAF mutations in nevi. Nat. Genet., 33(1), 19-20.10.1038/ng105412447372]Search in Google Scholar
[Poynter, J.N., Elder, J.T., Fullen, D.R., Nair, R.P., Soengas, M.S., Johnson, T.M., Redman, B., Thomas, N.E., Gruber, S.B. (2006). BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res., 16(4), 267-273.10.1097/01.cmr.0000222600.73179.f316845322]Search in Google Scholar
[Reifenberger, J., Knobbe, C.B., Sterzinger, A.A., Blaschke, B., Schulte, K.W., Ruzicka, T., Reifenberger, G. (2004). Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int. J. Cancer, 109(3), 377-384.10.1002/ijc.1172214961576]Search in Google Scholar
[Rhodes, A.R., Weinstock, M.A., Fitzpatrick, T.B., et al. (1987). Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA, 258(21), 3146-3154.10.1001/jama.1987.03400210088032]Search in Google Scholar
[Rodolfo, M., Daniotti, M., Vallacchi, V. (2004). Genetic progression of metastatic melanoma. Cancer Lett., 214(2), 133-147.10.1016/j.canlet.2004.06.04915363539]Search in Google Scholar
[Rusciano, D. (2000). Differentiation and metastasis in melanoma. Crit. Rev. Oncog., 11(2), 147-163.]Search in Google Scholar
[Saldanha, G., Purnell, D., Fletcher, A., Potter, L., Gillies, A., Pringle, J.H. (2004). High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer, 111(5), 705-710.10.1002/ijc.2032515252839]Search in Google Scholar
[Sasaki, Y., Niu, C., Makino, R., Kudo, C., Sun, C., Watanabe, H., Matsunaga, J., Takahashi, K., Tagami, H., Aiba, S., Horii, A. (2004). BRAF point mutations in primary melanoma show different prevalences by subtype. J. Invest. Dermatol., 123(1), 177-183.10.1111/j.0022-202X.2004.22722.x15191558]Search in Google Scholar
[Sharpless, N.E., DePinho, R.A. (2005). Cancer: Crime and punishment. Nature, 436(7051), 636-637.]Search in Google Scholar
[Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res., 64(19), 7002-7010.10.1158/0008-5472.CAN-04-139915466193]Search in Google Scholar
[Takeuchi, H., Kuo, C., Morton, D.L., Wang, H.J., Hoon, D.S. (2003). Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res., 63(2), 441-448.]Search in Google Scholar
[Thomas, N.E., Alexander, A., Edmiston, S.N., Parrish, E., Millikan, R.C., Berwick, M., Groben, P., Ollila, D.W., Mattingly, D., Conway, K. (2004). Tandem BRAF mutations in primary invasive melanomas. J. Invest. Dermatol., 122(5), 1245-1250.10.1111/j.0022-202X.2004.22523.x15140228]Search in Google Scholar
[Tsao, H., Goel, V., Wu, H., Yang, G., Haluska, F.G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol., 122(2), 337-341.10.1046/j.0022-202X.2004.22243.x258666815009714]Search in Google Scholar
[Tsao, H., Zhang, X., Fowlkes, K., Haluska, F.G. (2000). Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res., 60(7), 1800-1804.]Search in Google Scholar
[Uribe, P., Wistuba, I.I., Gonzalez, S. (2003). BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Amer. J. Dermatopathol., 25(5), 365-670.10.1097/00000372-200310000-0000114501284]Search in Google Scholar
[van Elsas, A., Zerp, S.F., van der Flier, S., Kruse, K.M., Aarnoudse, C., Hayward, N.K., Ruiter, D.J., Schrier, P.I. (1996). Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Amer. J. Pathol., 149(3), 883-893.]Search in Google Scholar
[Williams, M.L., Sagebiel, R.W. (1994). Melanoma risk factors and atypical moles. West. J. Med., 160(4), 343-350.]Search in Google Scholar
[Wu, H., Goel, V., Haluska, F.G. (2003). PTEN signaling pathways in melanoma. Oncogene, 22(20), 3113-3122.10.1038/sj.onc.1206451]Search in Google Scholar
[Yazdi, A.S., Palmedo, G., Flaig, M.J., Puchta, U., Reckwerth, A., Rutten, A., Mentzel, T., Hugel, H., Hantschke, M., Schmid-Wendtner, M.H., Kutzner, H., Sander, C.A. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol., 121(5), 1160-1162.10.1046/j.1523-1747.2003.12559.x]Search in Google Scholar
[Zhang, Y., Xiong, Y., Yarbrough, W.G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92(6), 725-734.10.1016/S0092-8674(00)81401-4]Search in Google Scholar